Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms.

Monaco F, Scott BL, Chauncey TR, Petersen FB, Storer BE, Baron F, Flowers ME, Deeg HJ, Maloney DG, Storb R, Sandmaier BM.

Haematologica. 2019 Jun;104(6):1221-1229. doi: 10.3324/haematol.2018.199398. Epub 2019 Jan 10.

2.

Decrease in Vancomycin-Resistant Enterococcus Colonization After Extensive Renovation of a Unit Dedicated to the Treatment of Hematologic Malignancies and Hematopoietic Stem-Cell Transplantation.

Ford CD, Gazdik Stofer MA, Coombs J, Lopansri BK, Webb BJ, Motyckova G, Petersen FB.

Infect Control Hosp Epidemiol. 2017 Sep;38(9):1055-1061. doi: 10.1017/ice.2017.138. Epub 2017 Jul 20.

PMID:
28724453
3.

Prediction of Bloodstream Infection Due to Vancomycin-Resistant Enterococcus in Patients Undergoing Leukemia Induction or Hematopoietic Stem-Cell Transplantation.

Webb BJ, Healy R, Majers J, Burr Z, Gazdik M, Lopansri B, Hoda D, Petersen FB, Ford C.

Clin Infect Dis. 2017 Jun 15;64(12):1753-1759. doi: 10.1093/cid/cix232.

PMID:
28369204
4.

Vancomycin-Resistant Enterococcus Colonization and Bacteremia and Hematopoietic Stem Cell Transplantation Outcomes.

Ford CD, Gazdik MA, Lopansri BK, Webb B, Mitchell B, Coombs J, Hoda D, Petersen FB.

Biol Blood Marrow Transplant. 2017 Feb;23(2):340-346. doi: 10.1016/j.bbmt.2016.11.017. Epub 2016 Nov 23.

5.

Room contamination, patient colonization pressure, and the risk of vancomycin-resistant Enterococcus colonization on a unit dedicated to the treatment of hematologic malignancies and hematopoietic stem cell transplantation.

Ford CD, Lopansri BK, Gazdik MA, Webb B, Snow GL, Hoda D, Adams B, Petersen FB.

Am J Infect Control. 2016 Oct 1;44(10):1110-1115. doi: 10.1016/j.ajic.2016.03.044. Epub 2016 Jun 7.

PMID:
27287734
6.

Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.

Webb BJ, Brunner A, Ford CD, Gazdik MA, Petersen FB, Hoda D.

Transpl Infect Dis. 2016 Aug;18(4):628-33. doi: 10.1111/tid.12550. Epub 2016 Jul 5.

PMID:
27214585
7.

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation.

Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Bazarbachi A, Blaise D, Ciceri F, Corbacioglu S, Dalle JH, Dignan F, Fukuda T, Huynh A, Masszi T, Michallet M, Nagler A, NiChonghaile M, Okamoto S, Pagliuca A, Peters C, Petersen FB, Richardson PG, Ruutu T, Savani BN, Wallhult E, Yakoub-Agha I, Duarte RF, Carreras E.

Bone Marrow Transplant. 2016 Jul;51(7):906-12. doi: 10.1038/bmt.2016.130. Epub 2016 May 16.

8.

The clinical impact of vancomycin-resistant Enterococcus colonization and bloodstream infection in patients undergoing autologous transplantation.

Ford CD, Lopansri BK, Gazdik MA, Snow GL, Webb BJ, Konopa KL, Petersen FB.

Transpl Infect Dis. 2015 Oct;17(5):688-94. doi: 10.1111/tid.12433. Epub 2015 Oct 3.

PMID:
26256692
9.

Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT).

Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Bazarbachi A, Blaise D, Ciceri F, Corbacioglu S, Dalle JH, Duarte RF, Fukuda T, Huynh A, Masszi T, Michallet M, Nagler A, NiChonghaile M, Pagluica T, Peters C, Petersen FB, Richardson PG, Ruutu T, Savani BN, Wallhult E, Yakoub-Agha I, Carreras E.

Bone Marrow Transplant. 2015 Jun;50(6):781-9. doi: 10.1038/bmt.2015.52. Epub 2015 Mar 23. Review.

10.

A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.

Kornblit B, Maloney DG, Storer BE, Maris MB, Vindeløv L, Hari P, Langston AA, Pulsipher MA, Bethge WA, Chauncey TR, Lange T, Petersen FB, Hübel K, Woolfrey AE, Flowers ME, Storb R, Sandmaier BM.

Haematologica. 2014 Oct;99(10):1624-31. doi: 10.3324/haematol.2014.108340. Epub 2014 Aug 1.

11.

Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.

Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, Shaughnessy P, Snyder E, Bensinger W, Copelan E, Hosing C, Negrin R, Petersen FB, Rondelli D, Soiffer R, Leather H, Pazzalia A, Devine S.

Biol Blood Marrow Transplant. 2014 Mar;20(3):295-308. doi: 10.1016/j.bbmt.2013.10.013. Epub 2013 Oct 17. Review.

12.

Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.

Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V, Maziarz RT, Chauncey TR, Pulsipher MA, Bruno B, Petersen FB, Bethge WA, Hübel K, Bouvier ME, Fukuda T, Storer BE, Sandmaier BM.

Biol Blood Marrow Transplant. 2013 Sep;19(9):1340-7. doi: 10.1016/j.bbmt.2013.06.002. Epub 2013 Jun 11.

13.

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM.

J Clin Oncol. 2013 Apr 20;31(12):1530-8. doi: 10.1200/JCO.2012.45.0247. Epub 2013 Mar 11.

14.

Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin.

Ostronoff F, Milano F, Gooley T, Gutman JA, McSweeney P, Petersen FB, Sandmaier BM, Storb R, Delaney C.

Bone Marrow Transplant. 2013 Jun;48(6):782-6. doi: 10.1038/bmt.2012.243. Epub 2012 Dec 17.

15.

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.

Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P, Pulsipher MA, Bethge W, Sahebi F, Bruno B, Maris MB, Yeager A, Petersen FB, Vindeløv L, McSweeney PA, Hübel K, Mielcarek M, Georges GE, Niederwieser D, Blume KG, Maloney DG, Storb R.

JAMA. 2011 Nov 2;306(17):1874-83. doi: 10.1001/jama.2011.1558.

16.

Which dose of busulfan is best?

Johnson-Davis KL, McMillin GA, Juenke JM, Ford CD, Petersen FB.

Clin Chem. 2010 Jul;56(7):1061-4. doi: 10.1373/clinchem.2009.134940. No abstract available.

17.

Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.

Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, Langston AA, Pulsipher MA, Bredeson CN, Maziarz RT, Bruno B, Petersen FB, Maris MB, Agura E, Yeager A, Bethge W, Sahebi F, Appelbaum FR, Maloney DG, Sandmaier BM.

J Clin Oncol. 2010 Jun 10;28(17):2859-67. doi: 10.1200/JCO.2009.27.1460. Epub 2010 May 3.

18.

Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial.

Nakamae H, Storer BE, Storb R, Storek J, Chauncey TR, Pulsipher MA, Petersen FB, Wade JC, Maris MB, Bruno B, Panse J, Petersdorf E, Woolfrey A, Maloney DG, Sandmaier BM.

Biol Blood Marrow Transplant. 2010 Mar;16(3):384-94. doi: 10.1016/j.bbmt.2009.11.004. Epub 2009 Nov 10.

19.

CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT.

Ford CD, Asch J, Konopa K, Petersen FB.

Bone Marrow Transplant. 2010 Feb;45(2):403-4. doi: 10.1038/bmt.2009.146. Epub 2009 Jul 13. No abstract available.

PMID:
19597424
20.

Maximum supportive care, standard conditioning and allogeneic stem cell transplantation for elderly patients with acute myelogenous leukemia.

Petersen FB, Ford CD.

Curr Opin Oncol. 2009 Jun;21 Suppl 1:S7-9. doi: 10.1097/01.cco.0000357468.45843.5e. Review.

PMID:
19561415
21.

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.

Burroughs LM, O'Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, Jones RJ, Ambinder RF, Maris MB, Blume KG, Niederwieser DW, Bruno B, Maziarz RT, Pulsipher MA, Petersen FB, Storb R, Fuchs EJ, Maloney DG.

Biol Blood Marrow Transplant. 2008 Nov;14(11):1279-87. doi: 10.1016/j.bbmt.2008.08.014.

22.

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.

Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, Maris MB, Agura ED, Chauncey TR, Wong RM, Forman SJ, Petersen FB, Wade JC, Epner E, Bruno B, Bethge WA, Curtin PT, Maloney DG, Blume KG, Storb RF.

Biol Blood Marrow Transplant. 2008 Feb;14(2):246-55. doi: 10.1016/j.bbmt.2007.11.012.

24.

Good and poor mobilizing patients differ in mobilized CD34+ cell adhesion molecule profiles.

Ford CD, Greenwood J, Anderson J, Handrahan D, Petersen FB.

Transfusion. 2004 Dec;44(12):1769-73.

PMID:
15584993
25.

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.

Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ; Caspofungin Salvage Aspergillosis Study Group.

Clin Infect Dis. 2004 Dec 1;39(11):1563-71. Epub 2004 Nov 9.

PMID:
15578352
27.

Effect of prior chemotherapy on hematopoietic stem cell mobilization.

Ford CD, Green W, Warenski S, Petersen FB.

Bone Marrow Transplant. 2004 May;33(9):901-5.

PMID:
15004541
28.

Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission.

Vose JM, Rizzo DJ, Tao-Wu J, Armitage JO, Bashey A, Burns LJ, Christiansen NP, Freytes CO, Gale RP, Gibson J, Giralt SA, Herzig RH, Lemaistre CF, McCarthy PL Jr, Nimer SD, Petersen FB, Schenkein DP, Wiernik PH, Wiley JM, Loberiza FR, Lazarus HM, van Biesen K, Horowitz MM.

Biol Blood Marrow Transplant. 2004 Feb;10(2):116-27.

30.
31.

Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.

Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB, Territo MC; Valacyclovir Cytomegalovirus Study Group.

Clin Infect Dis. 2003 Mar 15;36(6):749-58. Epub 2003 Mar 3.

PMID:
12627359
32.

A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.

Winston DJ, Antin JH, Wolff SN, Bierer BE, Small T, Miller KB, Linker C, Kaizer H, Lazarus HM, Petersen FB, Cowan MJ, Ho WG, Wingard JR, Schiller GJ, Territo MC, Jiao J, Petrarca MA, Tonetta SA.

Bone Marrow Transplant. 2001 Jul;28(2):187-96.

33.

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.

Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D, Fitzsimmons W, Anasetti C, Storb R, Ratanatharathorn V.

Blood. 2000 Sep 15;96(6):2062-8.

34.

Cytokeratin-positive cells in PBSC collections from normal donors and patients with non-epithelial cell-derived tumors.

Bills AC, Green WF, Tsodikov A, Carey MJ, Perkins SL, Petersen FB, Beatty PG, Kelley LL.

Cytotherapy. 1999;1(5):389-9.

PMID:
20440913
35.

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.

Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR.

Blood. 1998 Oct 1;92(7):2303-14.

36.

Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.

Demirer T, Petersen FB, Bensinger WI, Appelbaum FR, Fefer A, Rowley S, Sanders J, Chauncey T, Storb R, Lilleby K, Buckner CD.

Bone Marrow Transplant. 1996 Jul;18(1):29-34.

PMID:
8831992
37.

Allogeneic marrow transplantation following cyclophosphamide and escalating doses of hyperfractionated total body irradiation in patients with advanced lymphoid malignancies: a Phase I/II trial.

Demirer T, Petersen FB, Appelbaum FR, Barnett TA, Sanders J, Deeg HJ, Storb R, Doney K, Bensinger WI, Shannon-Dorcy K, et al.

Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):1103-9.

PMID:
7607931
38.

Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia.

Demirer T, Buckner CD, Appelbaum FR, Petersen FB, Rowley S, Weaver CH, Lilleby K, Sanders J, Chauncey T, Storb R, et al.

Bone Marrow Transplant. 1995 Jun;15(6):915-22.

PMID:
7581091
39.

Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation.

Demirer T, Gooley T, Buckner CD, Petersen FB, Lilleby K, Rowley S, Sanders J, Storb R, Appelbaum FR, Bensinger WI.

Bone Marrow Transplant. 1995 Jun;15(6):907-13.

PMID:
7581090
40.

High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.

Demirer T, Weaver CH, Buckner CD, Petersen FB, Bensinger WI, Sanders J, Clift RA, Lilleby K, Anasetti C, Martin P, et al.

J Clin Oncol. 1995 Mar;13(3):596-602.

PMID:
7884421
41.

Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies.

Lynch MH, Petersen FB, Appelbaum FR, Bensinger WI, Clift RA, Storb R, Sanders JE, Hansen JA, Buckner CD.

Bone Marrow Transplant. 1995 Jan;15(1):59-64.

PMID:
7742756
42.

High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma.

Weaver CH, Petersen FB, Appelbaum FR, Bensinger WI, Press O, Martin P, Sandmaier B, Deeg HJ, Hansen JA, Brunvand M, et al.

J Clin Oncol. 1994 Dec;12(12):2559-66.

PMID:
7989929
43.

The prophylactic use of low-dose amphotericin B in bone marrow transplant patients.

Riley DK, Pavia AT, Beatty PG, Petersen FB, Spruance JL, Stokes R, Evans TG.

Am J Med. 1994 Dec;97(6):509-14.

PMID:
7985709
44.

Comparison of morbidity and mortality after marrow transplantation from HLA-genotypically identical siblings and HLA-phenotypically identical unrelated donors.

Bearman SI, Mori M, Beatty PG, Meyer WG, Buckner CD, Petersen FB, Sanders JE, Anasetti C, Martin P, Appelbaum FR, et al.

Bone Marrow Transplant. 1994 Jan;13(1):31-5.

PMID:
8019451
45.

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.

Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, Petersen FB, Crawford SW, Press OW, Sanders JE, et al.

J Clin Oncol. 1993 Dec;11(12):2342-50.

PMID:
8246023
46.

Autologous bone marrow transplantation for acute lymphoblastic leukemia.

Doney K, Buckner CD, Fisher L, Petersen FB, Sanders J, Appelbaum FR, Anasetti C, Badger C, Bensinger W, Deeg HJ, et al.

Bone Marrow Transplant. 1993 Oct;12(4):315-21.

PMID:
8275030
47.

Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia.

Benyunes MC, Massumoto C, York A, Higuchi CM, Buckner CD, Thompson JA, Petersen FB, Fefer A.

Bone Marrow Transplant. 1993 Aug;12(2):159-63.

PMID:
8401364
48.

Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission.

Petersen FB, Lynch MH, Clift RA, Appelbaum FR, Sanders JE, Bensinger WI, Benyunes MC, Doney K, Fefer A, Martin P, et al.

J Clin Oncol. 1993 Jul;11(7):1353-60.

PMID:
8315433
49.

High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.

Weaver CH, Appelbaum FR, Petersen FB, Clift R, Singer J, Press O, Bensinger W, Bianco J, Martin P, Anasetti C, et al.

J Clin Oncol. 1993 Jul;11(7):1329-35.

PMID:
8315430
50.

Follow-up report on the outcome of patients relapsing after autologous marrow transplantation for malignant lymphoma.

Weaver CH, Appelbaum F, Petersen FB, Buckner CD.

J Clin Oncol. 1993 Apr;11(4):812-3. No abstract available.

PMID:
8478675

Supplemental Content

Loading ...
Support Center